​Developing novel small molecules as a therapeutic for coronary artery inflammation and consequential disease

Prokardia was founded by Professor Gemma Figtree - Head of the Australian Cardiovascular Alliance and Professor Michael Kassiou - Academic Director, The University of Sydney Drug Discovery Initiative.

​

Chronic low-grade inflammation contributes to the development of cardiovascular disease and the P2X7 receptor mediates inflammation and cellular death. Activation of P2X7R increases IL-1β and IL-18 which have been implicated in the development of many cardiovascular conditions including pulmonary hypertension and atherosclerosis.